Bull case
Immuneering is viewed positively because atebimetinib’s Deep Cyclic Inhibition appears to solve a long-standing MEK problem: delivering strong MAPK suppression without the chronic toxicity that has historically limited the class, which could make it a broadly useful backbone across KRAS/RAS-driven tumors. The clinical package in first-line PDAC is compelling, with 17.3-month median overall survival, 8.3-month median PFS, 36% ORR, 82% DCR, and 84% of patients maintaining or gaining weight, while safety remained clean enough that only anemia and neutropenia were prominent grade 3+ events and only one of 55 patients discontinued atebimetinib for reasons not attributed to toxicity. With about $199 million of cash and runway into 2029, the company has time to reach MAPKeeper 301, and the durable signal across 34 to 55 patients supports confidence that the opportunity extends beyond a single data cut.